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A number of techniques temporarily lower the functioning of monoamines: acute tryptophan
depletion (ATD), alpha-methyl-para-tyrosine (AMPT) and acute phenylalanine/tyrosine deple-
tion (APTD). This paper reviews the results of monoamine depletion studies in humans for the
period 1966 until December 2002. The evidence suggests that all three interventions are
specific, in terms of their short-term effects on one or two neurotransmitter systems, rather
than on brain protein metabolism in general. The AMPT procedure is somewhat less specific,
affecting both the dopamine and norepinephrine systems. The behavioral effects of ATD and
AMPT are remarkably similar. Neither procedure has an immediate effect on the symptoms of
depressed patients; however, both induce transient depressive symptoms in some remitted
depressed patients. The magnitude of the effects, response rate and quality of response are
also comparable. APTD has not been studied in recovered major depressive patients. Despite
the similarities, the effects are distinctive in that ATD affects a subgroup of recently remitted
patients treated with serotonergic medications, whereas AMPT affects recently remitted
patients treated with noradrenergic medications. The evidence also suggests that ATD and
APTD affect different cognitive functions, in particular different memory systems. Few studies
investigated cognitive effects of the procedures in patients. Patients who are in remission for
longer may also be vulnerable to ATD and AMPT, but the relationship with prior treatment is
much weaker. For these patients, individual vulnerability markers are the more important
determinants of depressive response, making these techniques potentially useful models of
vulnerability to depression.
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Introduction
Monoamines play a role in the regulation of mood and
cognitive functions, and low monoamine function is
associated with a range of psychopathological condi-
tions, particularly with mood and anxiety disorders.
Consistent with these notions, medications that
augment the activity of the monoamine systems
(tricyclic antidepressants (TCAs), selective serotonin
re-uptake inhibitors (SSRIs) and monoamine oxidase
inhibitors (MAOIs)) are effective medications for
anxiety disorders and for depression.1,2
A number of experimental procedures can be
employed to investigate the role of monoamine
neurotransmission in psychopathology. These in-
clude administration of drugs (eg receptor-specific
agonists or antagonists) and methods that lower
monoamine functioning by restricting the intake of
precursor amino acids (AAs) and/or blocking their
synthesis (depletion methods). Lowered catechola-
mine (CA) brain function can be investigated experi-
mentally in two ways: blocking its synthesis by
administration of alpha-methyl-para-tyrosine
(AMPT), or by dietary restriction of its immediate
precursors phenylalanine and tyrosine: acute pheny-
lalanine/tyrosine depletion (APTD). Lowered seroto-
nin (5-HT) neurotransmission can be induced
experimentally by the acute tryptophan depletion
(ATD) method. ATD involves dietary restriction of the
5-HT precursor l-tryptophan (Trp), in combination
with the consumption of a large quantity of other AAs
that compete with Trp at the blood–brain barrier.3
Central 5-HT function can also be lowered by
administration of para-chlorophenylalanine (PCPA),
a selective inhibitor of Trp hydroxylase. However, the
use of this procedure is limited by its toxicity.4
Monoamine depletion research has had important
implications for biological theories of depression. For
instance, the earlier idea of an absolute deficit in 5-HT
neurotransmission as a primary cause of mood
disorders, or as a predictor of response to 5-HT-
enhancing medications, has proven to be untenable.
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Incompatible with a simple, low 5-HT model of
depression are the findings that ATD does not worsen
the symptoms of currently depressed patients5 and
that ATD induces no symptoms or only mild
dysphoria in healthy volunteers.3 The concept of
‘serotonergic vulnerability’ more adequately de-
scribes the association between serotonin and depres-
sion. The categorical view (ie low 5-HT is
characteristic of specific diseases) has been replaced
by the dimensional view that impaired 5-HT function
(eg as reflected in a mood response to ATD) is a
manifestation of a vulnerability to mood lability and/
or cognitive dysfunction, across different diseases.6,7
According to this view, impaired 5-HT function
signifies the presence of a biological risk factor,
resulting from either genetic loading and/or early
environmental insult. Neither of these may be
sufficient; however, in combination with other genet-
ic factors and/or environmental stressors, this high-
risk model predicts the triggering and maintenance of
low mood and cognitive dysfunction. A similar
vulnerability model may be postulated for noradrener-
gic (NE) and dopaminergic (DA) neurotransmission.
Recently, many studies have investigated mood and
cognitive functioning before and after manipulations
of 5-HT or CA levels. The complex pattern of 5-HT
and DA effects on behavior is readily apparent
when considering the major pathways of these
neurotransmitters in the central nervous system
(CNS). However, by focusing on differences, simila-
rities and interactions, hypotheses may be generated
about the specificity of effects of manipulating single
neurotransmitter dimensions. The lowering of both 5-
HT and DA may be expected to induce negative affect,
since negative affect may be the result of many
different projections. However, differential effects—
on the level of symptoms, neuropsychological func-
tions or hormonal responses—may also be expected.
Typical findings associated with low 5-HT function
are: increased anxiety and depression, increased
appetite, increased aggression due to impaired im-
pulse control, increased cortisol levels and a de-
creased cortisol response to neuroendocrine and
stress challenges and impaired cognitive functioning,
in particular memory consolidation.8–10 Low CA
function (in particular, low DA) is typically asso-
ciated with proneness to addiction, decreased vigor,
impaired emotional memory, increased prolactin and
impaired working memory.11–14
The purpose of this paper is to review monoamine
depletion studies in humans: ATD, AMPT and APTD.
The specificity of these procedures as manipulations
of 5-HT and CA function (with an emphasis on DA)
will be assessed. For this purpose, the effects of these
challenges in psychiatric patients as well as in
healthy individuals will be reviewed. The following
hypotheses will be tested: (1) there are distinct and
dissociable influences of manipulations of 5-HT vs
CA neurotransmitters on behavioral parameters
(mood and cognition) and (2) these challenges are
meaningful models of vulnerability to mood disor-
ders, particularly major depression. A review of the
ATD method has recently been published.15 Since this
procedure continues to be used intensively, the
present paper will present an update of findings
published between July 1999 and December 2002.
Materials and methods
Electronic libraries (Medline and Web of Science)
were used to identify relevant literature on mono-
amine depletion studies (period between 1966 and
December 2002). The keywords used were ‘AMPT’,
‘tryptophan depletion’, ‘catecholamine depletion’,
‘APTD’ and ‘tyrosine depletion’. In addition, refer-
ence lists of the retrieved papers were checked.
Results
Acute tryptophan depletion
Mechanism, procedure ATD commonly involves the
restriction of Trp intake during 1 day, followed by the
consumption of a large quantity of AAs, but no Trp,
the next day morning. The usual amount is 100 g,
mixed with 300 ml water and artificial flavor.3 The
AAs stimulate protein synthesis, which requires Trp,
while Trp competes at a relative disadvantage for
the same transport system into the brain. When using
a 100 g AA mixture, plasma levels of Trp drop by
70–90% within 4–7 h after consumption of the drink.
Some studies do not employ the 24-h dietary
restriction of Trp prior to ingestion of the AA drink.
Other ATD studies have used only essential AAs.
Another variation is the use of lower dosages (75 g or
even 50 g or 31.5 g AAs), which usually (but not
always) results in plasma Trp reductions of 60–80%.
The physiological effects of ATD appear to be
specific for 5-HT: its metabolite 5-HIAA in CSF
is reduced after ATD, whereas homovanillic acid
or other metabolites are not reduced.16 A more
detailed explanation of the procedure can be found
elsewhere.3,4
Two control procedures are commonly used: one in
which a small amount of Trp is added to the AA
mixture, and one in which 25 g instead of 100 g of
AAs is consumed.17 The latter procedure was used in
the United States during the 1990s, when Trp was
banned from the US market. The results are not the
same: the first procedure leads to a rise in plasma Trp
that can vary in size, whereas the latter procedure
usually leads to modest reductions of plasma Trp.
As central 5-HT function depends on Trp as well as
on large neutral amino acids (LNAAs), the Trp/LNAA
ratio in plasma is a better index of central 5-HT
function than plasma Trp. Some studies still fail to
report Trp/LNAA ratios, although it was demon-
strated many years ago that Trp/LNAA ratios may
decrease while plasma Trp levels increase.18 Both the
ATD and control procedures have the drawback that
the AA mixtures taste unpleasant and have side
effects, in particular nausea and vomiting. Some
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researchers have administered some or all of the AAs
in capsules. The amount of AAs is then reduced to
31.5 g, still requiring 50 capsules. This procedure has
been shown to induce sufficient depletion,19 and may
also cause fewer side effects, although there are
insufficient data to determine whether side effects
are prevented. Up to 25% dropout rates have been
reported due to side effects, although in most studies,
dropout rates have been low.20 Nevertheless, the
introduction of a new, protein-based Trp depletion
method may be an important development in terms of
tolerability.21,22 This procedure uses a gelatin-based
protein comprising the entire range of AAs (except
Trp) in the form of peptides.21,22 A second potential
advantage of this new method is that much higher
reductions of Trp were found in rats than are usually
obtained with the AA method.23,24 However, no
studies on this new ATD method in humans have
yet been published.
Prior review A previous review of the literature up to
July 199915 showed that ATD has a mood-lowering
effect in subgroups of recovered depressed patients,
patients with seasonal affective disorder (SAD) and in
genetically vulnerable, healthy subjects. The mood
effect in former patients is much larger, and also
seems to be of a different quality than the effect in
vulnerable healthy subjects. The response to ATD was
clearly associated with prior treatment with
medication affecting the 5-HT system. In SSRI-
treated patients, the ‘relapse’ rates during ATD were
50–60%, and several recent studies failed to produce
the effect. Preliminary evidence existed for an effect
of ATD on bulimia nervosa, autism, aggression and
substance dependence.
Behavioral effects in patients with mood disorders and
in genetically vulnerable individuals Although the
mood-lowering effect of ATD in a subgroup of
recovered depressed patients, particularly those
who had been treated or were still being treated
with an SSRI, was already well established at the
time of our previous review, a number of studies
had not been able to replicate the effect. Further
research support, however, has since become
available.25–28 Although each of these studies
comprised a relatively small number of patients, the
replications are important because of the negative
findings mentioned above.
The serotonergic treatment specificity of response
to ATD also received further support. In a study with
20 bipolar and 10 unipolar depressed patients who
were all stabilized on lithium treatment, no clinically
relevant mood changes were induced by ATD.29 The
same result was found in a study with 19 lithium-
treated patients with bipolar-I disorder.30 This corro-
borates two earlier studies that had shown that
euthymic patients who were being treated with
lithium were unaffected by ATD.31,32 Bipolar patients
treated with an SSRI, however, are probably as
vulnerable to ATD as unipolar patients.15
More is known now about what other factors
determine response to ATD in recovered depressed
patients. This question had arisen not only because of
the occasional unsuccessful attempt to replicate, but
also because of the common finding that even in
SSRI-treated patients, no more than 50–60% respond
to ATD. Previous attempts to find predictors of
response28,33,34 had been inconclusive because of the
substantial number of cases that is needed for
prediction studies. In a recent study, the data from
six prior ATD studies were pooled and reanalyzed, in
order to increase statistical power. Results showed
that chronicity (more than one prior episode), SSRI
treatment, gender (female), and previous serious
suicidal thoughts or behaviors are independent
predictors of depressive response to ATD.20 Chroni-
city of illness was the most powerful predictor,
whereas residual depressive symptoms were not
found to predict response to ATD. Comparison of
these findings with those of Delgado et al,35–37 which
were not included in the reanalysis, suggests that
depressive response to ATD may reflect: (1) the
mechanism of action of SSRIs (if ATD is applied soon
after onset of remission); or (2) individual differences
in biological vulnerability to depression (if ATD is
applied during a later phase of remission). This
concept of ATD as a model of vulnerability to
depression may be independently validated by study-
ing the response to ATD of healthy individuals who
may be genetically vulnerable to depression (this will
be further discussed below) and by brain imaging
studies.
A recent PET 5-HT2 receptor ligand-binding study,
mapping 5-HT2 binding potential using
18F-setoper-
one, showed a significant decrease in brain 5-HT2
receptor density following ATD in healthy women.38
No mood effects were observed in this study, and the
authors suggest that downregulation of 5-HT2 recep-
tors may have an adaptive function in the prevention
and relief of depressive symptoms. This hypothesis
could explain why patients treated with noradrener-
gic drugs typically do not respond to ATD, because
animal studies have shown that these drugs (in
contrast with SSRIs) consistently downregulate
5-HT2 receptors.
38 A study of ATD followed by Trp
infusion indicated that cortisol response to Trp is
enhanced by ATD.39 This phenomenon probably
reflects acute dysregulation of postsynaptic 5-HT2
receptors, which also occurs as a compensatory
response to stress and low 5-HT, in an attempt to
maintain normal 5-HT turnover.40 Theoretically, pro-
longed duration of stress and low 5-HT, the latter
putatively induced by the former, ultimately leads to
dysregulation of the 5-HT system.41
An important recent development concerns the
relationship between genetic variability and mood
response to ATD. Two studies, however, show contra-
dictory findings, albeit in different populations. Both
studies investigated the relationship between mood
response to ATD and a functional polymorphism of
the promoter region of the serotonin transporter gene
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(SLC6A4). In one of these studies, remitted depressed
patients who were homozygous for the long allele of
the promoter region had a mean change in Hamilton
ratings that was much larger than patients who were
heterozygous or homozygous for the short allele (11.0
vs 5.5 vs 3.4 points change, respectively).42 Patients in
this study were on diverse treatment regimes: 12 were
treatment-free, 19 were on SSRIs, three on other
medications and nine underwent cognitive therapy.
The sample size did not allow independent testing of
treatment history and other clinical variables asso-
ciated with response to ATD. Inconsistent with these
results, a larger response to ATD was associated with
the homozygous short genotype in 45 healthy women,
irrespective of a family history of depression.43 The
women with l/l genotype did not show a mood
response. Women with the s/l genotype and a family
history (FHþ ) had similar mood responses as the s/s
genotypes, whereas the s/l genotypes without family
history (FH) showed an intermediate mood re-
sponse. How to explain these contradictory findings?
Since both in vitro and in vivo studies have indicated
that the long allele is associated with higher basal and
induced transcriptional activity of the serotonin
transporter, the s/s allele pair could be expected to
be the most vulnerable genotype, and the hetero-
zygous genotypes intermediate.43 It could also be
argued that when the decreased availability of 5-HT
during ATD is combined with a greater uptake of
5-HT into the presynaptic cell (in l/l genotypes), a
greater decrease in 5-HT neurotransmission may
occur.42 Insufficient depletion has previously been
proposed as a potential explanation as to why the
response to ATD is so varied.44 This genetic varia-
bility may cause different extents of brain 5-HT
depletion, while peripheral markers of 5-HT function
are comparable. Although speculative, the fact that
the l/l genotype was observed to be the most
responsive to ATD in remitted patients42 could also
be due to the use of SSRIs. There is some evidence
that use of SSRIs alters or masks the effect of
vulnerability by scarring the neurotransmitter system,
at least shortly after the cessation of experimental
SSRI treatment of only 4 weeks. Healthy individuals
treated with fluoxetine had blunted hormonal re-
sponses to 5-HT1A challenge, indicative of down-
regulation of both pre- and postsynaptic 5-HT1A
receptors.45 Furthermore, 3-week treatment of healthy
volunteers with paroxetine led to desensitized 5-HT2
receptors as evidenced by a blunted prolactin re-
sponse.46 Since many participants in the Moreno et al
study were on SSRIs (and some may have been on
SSRIs in the past), one could speculate that SSRIs
may affect the function of 5-HT neurotransmission
particularly in l/l genotype individuals. It should also
be noted that the mood response to ATD in the study
with healthy women was remarkable: the average
change of Hamilton (21 item version) scores was
approximately 5.5 points in FHþ women and 3.1 in
FH women (averaged over genotypes). In prior ATD
studies using genetically vulnerable but healthy
samples, only small changes in mood, if any, were
detected. The effect of ATD on depression ratings in
this population is in fact so small that it was
inconclusive at the time of our earlier review.6,47
The evidence now indicates that healthy relatives of
patients with depression or bipolar disorder are more
vulnerable to the effects of ATD than individuals
without a family history of mood disorders,48–50 but
the mood effect is quite small. Furthermore, the large
change in the s/s genotype healthy sample occurred
despite the fact that a much smaller amount of AAs
(31.5 g) was used than that usually used in ATD
studies (100 g). The whole dosage was encapsulated,
however, which may have ensured sufficient deple-
tion (about 80% reduction of free and total plasma
Trp), and since this procedure is uncommon, it
cannot be ruled out that this has been responsible
for the large effect. Finally, perhaps clinical depres-
sion rating scales are more sensitive to the effects of
ATD than visual analogue ratings of mood states.
Although this may sound counterintuitive, in one
study with remitted patients a greater effect of ATD
was found on the Hamilton scale than on self-
ratings28 (this particular finding was not published).
In an ongoing study, different sensitivities of different
depression scales are being observed. Surprisingly,
the Hamilton scale has not been used previously in
ATD studies of healthy samples, so this may be
investigated further. To summarize, ATD was asso-
ciated with a larger mood response in l/l genotype
remitted patients, and in s/s genotype healthy
women. One possible explanation might be that
pharmacotherapy has different effects on 5-HT neu-
rotransmission in l/l and s/s individuals. However,
there are many differences between both studies.
Combined with the facts that the patient sample was
rather heterogeneous, and that the large mood
response in the healthy women is anomalous, a
replication of both studies seems warranted.
Family history seems to be a better predictor of
response to ATD than is neuroticism.51 Opposite
effects were found in subjects who had relatives with
either bipolar I or bipolar II disorder: the type II
relatives showed an elevation of mood, whereas the
type I relatives had a lower mood after ATD.50 In both
groups, but not in controls, cortisol levels decreased
after ATD. Although the cortisol response to stress
was attenuated after ATD, this was not statistically
significant.
At the time of our previous review, several studies
had already shown that remitted (light treatment)
SAD patients respond to ATD, whereas symptomatic
SAD patients do not. It has since been shown that
eight of 11 SAD patients who were in natural
remission during summer responded to ATD.52 This
study also showed that seven of eight SAD patients
who reacted to ATD in summer developed a depres-
sive episode during the next winter, whereas two of
three patients who did not respond to ATD remained
well.52 In another study on SAD during natural
summer remission,53 six of 12 medication-free
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patients had a clinically significant increase of
symptoms after ATD, but three patients also reacted
to sham depletion. As the difference was nonsignifi-
cant, it was concluded that summer remission is not
dependent on plasma Trp levels in the same manner
as remission after light therapy. This study has since
been cited as a failure to replicate,54,55 but this
conclusion is unwarranted: the 50% response rate to
ATD is well within the normal range.56 The response
to sham depletion was unusually high in this study,
which may have been due to unintended reductions
of the Trp/LNAA ratio during control sessions. Thus,
the evidence for the importance of 5-HT mechanisms
during summer remission is as strong as it is for
remission after light therapy.
Tryptophan depletion in other psychiatric
conditions Significant effects of ATD on patients
with bulimia nervosa (BN) have been confirmed. ATD
had a small effect on mood and desire to binge, but no
effect on food intake in 22 women with BN as
compared to 16 healthy women.57
The evidence in panic disorder had been mixed;
however, three recent studies have shown that ATD
increases the vulnerability of PD patients to provoca-
tion with flumazenil,58 5% CO2
59 and 35% CO2.
60 The
latter study found a possible protective effect of the
control condition (which often raises plasma Trp
levels).
In alcoholism, ATD does not seem to have an effect,
neither on the amount of alcohol consumed in an
experimental setting,61 nor on craving62 or mood.63
However, a cognitive effect was found in one of these
studies (see below).
One study on schizophrenia found no effect of ATD
on mood, psychotic symptoms or movement disor-
ders.64 Added to two earlier studies with very small
and opposite effects, it seems safe to conclude that
acute serotonin deficiency induced by ATD does not
affect schizophrenia symptoms. However, it may
affect executive function, as assessed by a neuropsy-
chological planning test.64
Tryptophan depletion and aggression The
relationship between serotonin and aggression
continues to be an important and fruitful area of
research. At the time of our previous review, a
number of studies had shown that ATD increased
aggressive responses, particularly in individuals with
high trait aggression scores. However, negative
findings had also been published. It has again been
shown that ATD increased aggression in men with
high baseline levels of aggression, and also that ATD
does not affect aggressive behavior in men with low
baseline levels of aggression.65 Women who took ATD
during the premenstrual phase showed increased
aggression in response to provocation.66 In another
small study, mood effects of ATD were only observed
in high trait-aggressive women, and not in low trait-
aggressive women and men.67 The hightrait-
aggressive men in this study had relatively low
aggression scores, so these results are not
necessarily incompatible with Bjork et al. Another
study studied aggressive behavior in 12 women under
ATD conditions, Trp augmentation and fasting.68 Trp
augmentation decreased aggressive behavior and ATD
increased aggressive behavior. These effects were
restricted to women with higher plasma Trp during
the fasting control condition. In earlier studies with
men, Trp augmentation did not affect aggression.69
Furthermore, although self-reported (trait) aggression
and impulsiveness were unrelated to aggression
following ATD or Trp augmentation, these self-
reports were related to the women’s sensitivity
(change of plasma Trp levels) to ATD and Trp
augmentation.
In summary, these studies provide further support
for the relationship between 5-HT and aggression, and
also provide explanations for apparently conflicting
data by drawing attention to differences between men
and women, and between certain subgroups (in
particular, individuals with high trait aggression
scores or high plasma levels of Trp).
Cognitive effects of ATD in patients and healthy
samples Some general trends are emerging from
studies into the cognitive effects of ATD in normal
samples, despite the fact that researchers use many
different tests or test versions to measure cognitive
functions. ATD has a specific negative effect on long-
term memory (memory consolidation),70 irrespective
of family history for depression,49,71,72 and
particularly for words with positive or neutral
connotations.49.Furthermore, it has a positive effect
on focused attention as measured by Stroop word–
color interference.70 Performance on a planning task
(Tower of London) was impaired after ATD in first-
degree relatives of bipolar disorder patients,72 but not
in healthy volunteers.72,73 In euthymic bipolar
patients, the effect of ATD on planning was small
(statistically a trend) and there was no effect on
attention, vigilance and learning.74
Another study also points to the importance of
individual differences, in this case family history of
alcoholism. ATD had opposite effects on performance
on a behavioral inhibition task in 20 men with and 20
men without an alcoholic father (impaired and
improved performance, respectively).63 ATD had no
effect on mood in this study, nor did it affect
performance on a delay discounting task. Finally,
ATD caused a small but significant reduction of
scores on the Mini Mental State Examination in 16
patients with dementia of the Alzheimer type,75 while
it had no effect on the cortisol levels of Alzheimer
patients.76
Alpha-methyl-para-tyrosine
Mechanism, history and procedure The AA tyrosine
is the precursor of CA, DA and NE. After crossing the
blood–brain barrier, tyrosine is converted into 3,4-
dihydroxyphenylalanine (L-dopa) by the rate-limiting
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enzyme tyrosine hydroxylase. Next, L-dopa is
converted via aromatic L-amino acid decarboxylase
to DA and via DA-b-hydroxylase to NE.77 CA activity
in the CNS can be reduced by oral administration of
AMPT. AMPT temporarily reduces L-dopa availability
by blocking the enzyme tyrosine hydroxylase, which
consequently leads to reduced CA synthesis.77
Daily administration of AMPT (1–4 g/day) generally
reduces urinary and CSF levels of MHPG and HVA
(CA metabolites) by more than 50%. CSF levels of 5-
HIAA (metabolite of 5-HT) remain unchanged,78
indicating that the effects are specific. CA metabolite
levels are assumed to reach their minimum within
2–3 days after starting AMPT administration and
are normalized within 3–4 days after withdrawal of
the drug.77,79,80
Early treatment studies have shown that daily, long-
term treatment with AMPT could relieve symptoms in
those medical conditions in which an excess of CAs
may play a role, including phaeochromocytoma,81
hypertension, glaucoma or tardive dyskinesia,
whether or not in combination with conventional
medicines.79,81 The clinical use of AMPT in patients
with mood disorders has been investigated in the
1960s. In a sample of seven manic and three
psychotically depressed patients, administration of
2–4 g AMPT daily (5–48 days) decreased manic
symptoms in five patients, whereas the depressed
patients all became more depressed. Mood state
returned to baseline levels after discontinuation of
the drug, except for three manic patients who retained
the reduction in symptoms during the 5-day post-
AMPT observational period.78,80 In a treatment study
with 20 patients with essential hypertension, six had
a history of depression. Three of these depression-
prone patients experienced increased agitation after
receiving AMPT, requiring withdrawal of AMPT
treatment.79 To conclude, chronic AMPT treatment
generally does not affect mood in medically ill,
nonpsychiatric patients, but it may affect mood in
depressed patients or in individuals vulnerable to
mood disorders.
The first ‘challenge’ study in which AMPT was
used dates back to the mid-1970s. Three depressed
patients were concomitantly treated with AMPT after
they had responded well to 300 mg imipramine (a
tricyclic antidepressant). AMPT did not reverse the
imipramine response in any of these patients (two
unipolar, one bipolar), not even in a patient who
received AMPT daily prior to imipramine treatment
and continued to use it daily concomitant with
imipramine.82 In contrast, two imipramine respon-
ders (one unipolar, one bipolar patient) in the same
study temporarily relapsed within 2–3 days after
starting PCPA administration (a Trp hydroxylase
inhibitor). The authors concluded that 5-HT rather
than CAs may be involved in the mechanism of action
of imipramine.
The Yale group was the first to use the AMPT
challenge procedure for relatively short periods in a
placebo-controlled design. Since the early 1990s,
many experimental studies that used AMPT as a
challenge were published (Table 1). Nowadays the
AMPT depletion procedure usually involves a 48 h
study period in which participants receive a total
amount of 4–8 g AMPT in divided doses (1.5–4 g
daily) and a post-AMPT follow-up day. Placebo
testing usually consists of the administration of a
total amount of 250–500 mg diphenhydramide hydro-
chloride or promethazine.83,84 Both tests are active
placebos, since they induce comparable levels of
sedation.84,85 Usually, participants are kept on a low
monoamine diet during the study periods in order to
standardize food intake.
Although the dosages vary between AMPT chal-
lenge studies, the magnitude of reduction of CA
metabolites (measured in plasma) is generally equiva-
lent to the change in CA metabolite levels in urine
reported in the early treatment studies (Table 1). The
nature of the dose–response relationship is not clear,
as the few studies that use a higher dosage of AMPT
did not report HVA or MHPG levels. Maximum effects
occur within 1–2 days after starting AMPT adminis-
tration and disappear within 2–3 days after disconti-
nuation.83,86
Behavioral effects of AMPT in mood disorders In a
pilot study with 14 recently remitted depressed
patients who had responded well to NE re-uptake
inhibitors (NRIs) (n¼5) or SSRIs (n¼9), five patients
had a brief ‘full relapse’ following AMPT (ie 50%
increase on HRSD-25 and score Z18).83 This
depressive response appeared to be treatment
specific, as four of the five ‘responders’ had been
treated with an NRI. The pilot sample was enlarged,
and the findings were that eight of nine patients
treated with an NRI relapsed after AMPT (mean
Hamilton scores changed from 8.9 to 23.4), whereas
none of the 10 SSRI-treated patients relapsed.87 Not
all the SSRI responders from the pilot study were
included in the second report.
AMPT also led to a transient depressed mood in a
sample of 11 remitted depressed patients who had
responded well to mirtazapine (an antidepressant that
affects both the NE and 5-HT systems).88 Some of
these patients also responded to ATD (mean Hamilton
scores changed from 6 to 18). The effect sizes were
equivalent, but there were some differences when
symptoms were compared separately. Regarding
depression, both depletions led to loss of energy,
concentration problems and retardation. ATD also led
to depressed mood and somatic anxiety, whereas
AMPT led to decreased interest and agitation. It is of
interest that the effects of AMPT in mirtazapine-
treated patients (change score: 7) fall between the
effects in patients treated with an SSRI and those
treated with an NRI in the study by Miller et al87
(change scores 1.1 and 14.5, respectively).
The brief relapse following AMPT has been repli-
cated in a sample of medication-free fully remitted
depressed patients who were in remission for at least
4 months (mean 18 months).89 A total of 10 of 14
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Table 1 Summary of the results of AMPT challenge studies in humans
Study reference Population, design Treatment Total
AMPT
dosage (g)
% decline in plasma
AMPT
Main findings
HVA MHPG
Mood disorders
Shopsin et al82 3 MDD, 2 BP (2 males).
ImipramineþPCPA (1 MDD,
1 BP). ImipramineþAMPT
(2 MDD, 1BP). No placebo
Imipramine 3–4 g/day No ‘relapse’ after AMPT. 2/2
patients relapsed after PCPA
Delgado et al83 14 MDD (8 males). Remission.
HAMD-25r15. Within SS
design: AMPT/placebo
3 desipramine; 2 mazindol;
5 fluoxetine; 4 sertraline
5 71 44 4/5 NA-treated patients relapsed
after AMPT. 1/9 SSRI-treated
patients had a relapse
Miller et al87 19 MDD (13 males). Remission
42 weeks. HRSD r15. Within
SS design: AMPT/placebo
9 fluoxetine; 1 sertraline;
7 desipramine; 2 mazindol
5 86 51 8/9 NA-treated patients relapsed
after AMPT. 1/9 after placebo.
0/10 of SSRI-treated patients
relapsed
Miller et al85 17 MDE (13 males). HRSD Z20.
Within SS design: AMPT/placebo
Medication-free 5 70 50 No mood effect of AMPT. Slight
significant improvement after
placebo (HRSD: 31–424a)
Neumeister et al90 13 SAD (9 MDD, 4 BP; 4 males).
Remission Z2 weeks. SIGH-SAD
o12. Within SS design: AMPT/ATD/
placebo AMPT
Medication-freeZ6 months.
Last treatment:
light therapy
4 61 63 ATD: 10/13 patients relapsed
AMPT: 7/13 relapsed
Berman et al89 15 MDD (5 males). Remission
Z4 months. HRSD-25 o10.
Within SS design: AMPT/
placebo
Prior treatment: SSRI:
n¼10; SSRIþTCA/MAOI:
n¼2; TCA: n¼1; no
medication: n¼2
5 86 51 10/14 patients relapsed after
AMPT. 1/13 patients after
placebo
Anand et al86 8 BP patients (4 males).
Euthymic in remission. Within
SS design: AMPT/placebo
Lithium Z3 months 5 73a 65a No mood change during AMPT
Hypomanic symptoms 24–48 h
after last dose
Lam et al91 9 SAD (1 male). Summer
remission411 weeks. SIGH-SAD
r10. Within SS design:
AMPT/placebo
No treatment Z8 weeks 5 49 57 9/9 patients relapsed after
AMPT. 2/9 patients relapsed
after placebo
Berman et al92 10 MDE (5 males). Within SS
design: AMPTþATD/placebo
þATD
Medication-free 42 weeks 5 63 Not
reported
Small decrease in HRSD-25 after
AMPTþATD and
placeboþATD
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Delgado et al88 11 MDE (4 males). In remission. 10/11
with SSRI-induced sexual
dysfunction. Within SS design:
AMPT/ATD
Mirtazipine. Prior
medication: SSRI
(n¼10); St John’s wort (n¼1)
5 65 48 Increase in HRSD-25 after both
ATD and AMPT. No difference in
effect size between ATD and
AMPT
Other mental disorders
Stine et al96 10 cocaine users (8 males).
Within SS design:
AMPTþ cocaine/placeboþ
cocaine/placeboþAMPT/
placeboþplacebo
No treatment 3 84 64 AMPT increased prolactin
levels. AMPTþ cocaine
decreased feelings of ‘high’
(NS). No effect on cocaine
levels
Longhurst et al93 6 OCD patients (4 males); 4 with
comorbid depression. Within SS
design: AMPT/placebo
Medication-freeZ5
weeks. Prior treatment:
SSRI
9 Not
reported
Not
reported
No change in HRSD or Y-BOCS
scores
Abi-Dargham et al94 18 patients with schizophrenia (11
males). 18 controls (11 males).
Between SS design: baseline SPECT/
AMPTþSPECT. No placebo drug
No neuroleptics for
about 139 days
8 Not
reported
Not
reported
Effect of AMPT on D2 receptor
availability larger in patients
than in controls (9 vs19%).
AMPT reduced positive
symptoms in patients (decrease
PANSS positive scores: 3.7
points): inverse correlation with
change in D2 receptor binding.
D2 receptor binding after AMPT
predicted response to
antipsychotic treatment
Voruganti et al95 Between SS design. N¼2 6 patients.
With schizopherenia: ‘dysphoric’
responders to previous neuroleptic
drugs vs ‘nondysphoric’.
Baseline SPECT scan
vs AMPTþSPECT. No
placebo drug
Unmedicated.
Prior treatment: neuroleptica
8 Not
reported
Not
reported
Increased dysphoric symptoms
after AMPT. Effect larger in
‘dysphoric’ group. Reduced
psychotic symptoms after
AMPT. Inverse correlation
between change in receptor
binding ratio/change in
dysphoric symptoms. Increased
binding ratio in D2 receptors
after AMPT; effect more
pronounced in ‘nondysphoric’
group than in ‘dysphoric’ group
(19.1 vs 5.1%)
Table 1 Continued
Study reference Population, design Treatment Total
AMPT
dosage (g)
% decline in plasma
AMPT
Main findings
HVA MHPG
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Healthy samples
Tychsen and
Sitaram104
N¼3 (2 males) Within SS design:
AMPT/placebo
None 9 Not
reported
53%
(urine)
Increase in saccadic eye move-
ments (amplitude/frequency)
McCann et al100 N¼2 12 (males). Between SS design:
AMPT/AMPTþ 64h SD
None Max. 8.25 Not
reported
Not
reported
Dystonia in 5/24 males after
AMPT. Symptoms disappeared
after treatment with
diphenhydramine or massage
and posture change
McCann et al103 N¼4 10 (males). Between SS design:
AMPT/AMPTþ 40h SD/lactose/
lactoseþ 64h SD
None 5.25 Not
reported
Not
reported
Increased subjective sleepiness
after AMPT, SD or AMPTþSD.
Effect larger after AMPTþSD.
Decreased sleep latency after
AMPT, SD and AMPTþSD,
effect not larger after
AMPTþSD. Change in speed
and decreased accuracy after
AMPTþSD, small cognitive
effects after AMPT or SD alone.
AMPT and AMPTþSD
increased prolactin levels.
Difference between AMPT and
AMPTþSD not significant
McCann et al99 N¼4 10 (males). Between SS design:
AMPT/AMPTþ 40h SD/lactose/
lactoseþ 64h SD
None 5.25 Not
reported
Not
reported
AMPT and SD increased
sleepiness and fatigue and
decreased alertness; effects
larger in the AMPTþSD
condition. No mood effect after
AMPT or SD. AMPTþSD
increased negative mood
(POMS/VAS). Behavioral effects
persist 12–16 h after
discontinuation of AMPT
Zimmermann et al106 N¼7 (3 males). Within SS design:
AMPT/placebo
None 5 Not
reported
Not
reported
AMPT decreased nocturnal
melatonin secretion. 24-h
urinary 6-SM excretion
correlated highly with 24-h
melatonin secretion during
AMPT condition (r¼0.93)
McCann et al97 N¼4 10 (males). Between SS design:
AMPTþplacebo/AMPTþ L-dopa/
placeboþ L-dopa/placeboþplacebo
None 6 Not
reported
Not
reported
AMPT increased prolactin
levels. Effect reversed by L-
dopa. AMPT increased
sleepiness and anger and
decreased alertness, calmness
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and sleep latency. Slight
decrease in VAS happiness.
Effects on calmness, sleep and
alertness reversed by L-dopa
Zimmermann et al105 N¼10 (5 males). Within SS design:
AMPT/placebo
None 5 Not
reported
67%
(urine)
AMPT increased prolactin
levels; effect larger in females
than in males. AMPT decreased
24 h urinary 6-MS secretion. No
mood effect
Salomon et al101 N¼8 (4 males). Within SS design:
AMPTþ balanced amino-acid
mixture/AMPTþATD mixture
None 5 67%a 54%a No effect of AMPTþATD on
mood
Laruelle et al98 N¼11 (males). Baseline SPECT/
AMPTþSPECT. No placebo drug
None 6 70% 66% AMPT decreased VAS scores on
happiness, increased sleepiness,
restlessness, parkinsonism. No
effects on anxiety or energy.
Increased D2 receptor binding
potential (þ 28%)
Zimmermann et al107 N¼10 (5 males). Within SS design:
AMPT/placebo
None 5 Not
reported
67%
(urine)
No effect of AMPT on leptin
secretion
Krahn et al84 N¼10 (5 males). Within SS design:
AMPT/placebo
None 5 Not
reported
? Small increase after AMPT on
HRSD-25 (3 points). No effect on
POMS or HAM-A. Decreased
nocturnal and daytime urinary
6-SM excretion
Fujita et al108 N¼8. 2 baseline SPECT/
AMPTþSPECT. No placebo drug
None 5.5/70 kg
body
weight
64% 51% No change in PANSS subscales.
Increased D2 receptor ligands
binding in temporal cortex
(þ 13%), not in thalamus
(þ 1.8%). Significant
correlation between dysphoric
mood and potential binding in
the temporal cortex (r¼0.88)
Verhoeff et al102 N¼6 (4 males). Baseline PET/
AMPTþPET. No placebo drug
None 4.5 73% 53% AMPT increased VAS scores on
tiredness, sleepiness and
drowsiness and decreased
Table 1 Continued
Study reference Population, design Treatment Total
AMPT
dosage (g)
% decline in plasma
AMPT
Main findings
HVA MHPG
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patients had a relapse after AMPT, with HRSD-25
scores increasing from a mean of 3.1 to 23.9. A high
baseline cortisol level was associated with the
depressive response, whereas duration of remission,
history of medication use and changes in HVA or
MHPG levels were not.89 In contrast with the findings
in recently remitted samples,83,85,87 the depressive
response was unrelated to prior treatment. Of the 15
patients, 12 had been successfully treated with an
SSRI during their latest episode, and three had
received NRI treatment in the past. Thus, the
depressive response to AMPT may not only reflect
(prior) antidepressant mechanisms, but also reflect
individual vulnerability to depression.
Furthermore, AMPT induced clinically significant
depressive symptoms in seven of 13 patients with
SAD who had recently responded to light therapy.90
Six of these patients also responded to ATD, whereas
four patients only responded to ATD. In a sample of
nine SAD patients in summer remission, all patients
relapsed after AMPT.91
In a sample of eight recovered bipolar patients who
were stable on lithium, there was no mood effect
during AMPT administration. However, manic symp-
toms increased 24–48 h after discontinuation of
AMPT.86
In an early treatment study on symptomatic
depressed patients, all three patients had a depressive
response to AMPT.78 However, this finding seems to
be anomalous, as a later study found no mood change
in a sample of 17 unmedicated symptomatic de-
pressed patients.85 Combined AMPT and ATD had no
effect on mood in a sample of 13 unmedicated
depressed patients.92
AMPT in other psychiatric disorders AMPT had no
effect on symptoms or mood in a sample of six
unmedicated symptomatic patients with obsessive-
compulsive disorder (OCD).93 In unmedicated
patients with schizophrenia, AMPT led to a small
but significant improvement of psychotic
symptoms.94,95 In 12 drug-free symptomatic patients
with schizophrenia who had previously been treated
with neuroleptic medication, AMPT also induced
dysphoric symptoms.95 In a sample of 10 patients
with cocaine abuse, AMPT tended to reduce the
cocaine-induced feelings of ‘high’ (P¼0.10).96
AMPT in healthy volunteers AMPT generally does
not induce depressive symptoms in healthy
volunteers, as measured with the Hamilton
Depression Rating Scale. However, one study found
an average 3-point increase in Hamilton scores,
although there were no changes in self-report mood
ratings.84 Some studies in healthy samples found
small changes in the ratings of ‘happiness’ ‘anger’ or
‘tension’ using Visual Analogue Scales,97,98 but these
results are inconsistent. AMPT induced negative
mood when it was combined with 40.5 h sleep
deprivation.99 AMPT commonly has sedative effects,
including sleepiness, fatigue and decreased
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subjective alertness. Not all studies in healthy
samples use an active-sedative control drug. This
implies that the mood effects after AMPT in these
samples might be due to nonspecific side effects. In
some individuals, AMPT also induced dystonic
reactions,100 tremors and restlessness,98 which could
persist for 12 h after discontinuation of AMPT.
Administration of L-dopa reversed the AMPT-
induced effects on sleep, alertness and calmness,
but not on anger.97 ATD did not change the response
to AMPT in healthy volunteers.101
The effects of AMPT on cognitive functions have
also been investigated. In a D2 ligand-binding PET
study using 11C-raclopride in healthy volunteers,
AMPT impaired attention, which was associated with
increased raclopride binding potential, whereas psy-
chomotor speed remained unchanged.102 This study
did not include a placebo condition, but can never-
theless be taken to indicate that the effects of AMPT
on cognitive performance are associated with lowered
DA function. Another study reported decreased
performance on memory and attention tasks relative
to lactose administration when AMPT was followed
by 40 h sleep deprivation, but the effects were not
significant after AMPT or sleep deprivation alone.103
A small study (N¼3) also found that AMPT led to an
increase in saccadic eye movements.104
In summary, AMPT may slightly lower mood in
some healthy individuals. However, the mood effect
found in healthy samples is not comparable to the
effect observed in remitted depressed patients or
SAD patients. No studies were found that explicitly
focused on the mood or cognitive effects in healthy
first-degree relatives of depressed patients, or that
even mentioned psychiatric family history. Perhaps
the small inconsistencies are due to varying
numbers of genetically vulnerable participants in
the samples. However, methodological differences
between the studies may also be responsible. It
seems safe to conclude that, in nonvulnerable
individuals, AMPT has very small mood effects, if
any. The effects on attention and alertness are
also quite small, and appear to be modulated by
dopaminergic function.
Neuroendocrine effects of AMPT AMPT consistently
produced a two- to four-fold increase in prolactin (Prl)
levels (see Table 1). This is not surprising given that
DA inhibits Prl release.105.The magnitude of AMPT-
induced Prl release is related to gender, with women
showing a larger AMPT-induced Prl release than
males. Estradiol enhances the synthesis and release
of Prl by the pituitary gland, which may explain the
gender difference.106 Administration of AMPT also
decreased the nocturnal release of melatonin105,106
and the 24 h secretion of urinary 6-hydroxymelatonin
(6-MS) (melatonin metabolite).84,106 Leptin secretion
was not affected by AMPT.107 No studies were found
that investigated the effects on neuroendocrine
measures in patient samples.
Brain imaging studies and AMPT Since the AMPT
procedure is too short to affect D2 receptor
upregulation,98 the AMPT procedure combined with
imaging techniques has been used to study occupancy
of D2 receptors in the absence of any pharmacological
treatment (‘baseline levels’). Assuming complete
depletion of DA following AMPT, baseline DA
receptor occupancy can be estimated by comparing
the binding potential of D2 radiotracers before and
after AMPT administration, using single photo
emission computed tomography (SPECT)95,98,108 or
positron emission tomography (PET).102,109
Depending on the investigated sample, brain region,
magnitude of depletion in the synapse and possibly
on the type of radiotracer, AMPT increased D2
receptor binding potential in both patients and
healthy samples by 9–28% (see Table 1). At least in
healthy volunteers, AMPT does not affect D1 receptor
binding.109 In patients with schizophrenia, the
increase in receptor binding after AMPT is larger
than in controls.94 If behavioral changes in healthy
volunteers occur, increased receptor binding
(indicating higher ‘baseline’ synaptic DA activity)
has been found to correlate positively with these
changes in mood and cognition,98,102,108 although
there are also studies that found no relationship
with mood.109 In patients with schizophrenia, the
change in receptor binding in the striatum correlated
positively with positive symptoms.94 However, the
change in receptor binding was negatively associated
with the change in dysphoric symptoms following
AMPT in patients with schizophrenia.95 Interestingly,
the AMPT-induced increased D2 receptor binding
potential was associated with a decrease in positive
symptoms after 6 weeks of antipsychotic treatment.94
No imaging studies were found that investigated the
effects of AMPT in depressed patients.
Limitations of the AMPT method Although the
AMPT procedure facilitates the study of low CA
function under standardized conditions within a
relatively short time interval, there are some
limitations. Firstly, high amounts of AMPT may
cause sedation. It should be noted, however, that
sedation is an ill-defined concept, originating from
the clinical observation of overt drowsiness, caused
by an underlying general decrease of (sympathetic)
activation in the CNS. Claims of drug-induced
‘sedation’ are sometimes based on minute
prolongations of reaction times.110 Another pitfall of
the concept of sedation is the implicit assumption of
unidimensionality. However, when using fine-grained
measures, it appears that drugs may have sedative
effects in one system and stimulant effects in another
system. For instance, SSRIs impair vigilance111 but
enhance motor output and shorten reaction times.112
One study found dystonic reactions100 to AMPT,
which were alleviated by diphenhydramine adminis-
tration or massage and posture change. This probably
indicates that AMPT disturbed the cholinergic–
adrenergic balance. AMPT can also induce the
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Table 2 Summary of the results of APTD challenge studies in humans
References Population, design % reduction after APTD Main findings
Tyrosine Phenylalanine
Healthy volunteers
Moja et al116 N¼5 (5 males). Within SS design: 15.75 g
APTD/31.5 g APTD/fasting/19.05 g
placebo
45.2 (15.75 g) 40.4 (15.75 g) APTD decreased blood pressure
70.2 (31.5 g) 87.3 (31.5 g)
Sheehan et al120 N¼8 (5 males). Within SS design: 45.0 g
APTD/57.5 g placebo/water. Essential
amino acids only
50 40 No effect on evening melatonin levels
McTavish et al125 N¼15 (12 males). Between SS design: 90 g
APTDþD-amphetamine (n¼7)/115 g
placeboþ D-amphetamine (n¼8).
Essential amino acids only
68a Not reported APTD alone had no effect on mood
APTDþD-amphetamine decreased
VAS score on ‘mind racing’ and
increased ‘depression’
Leyton et al118,119 N¼41 females, screened for psychiatric
family history. Between SS design: 86.0 g
placebo (n¼14)/APTD (n¼12)/ATD
(n¼15)
76.5 52.6 APTD and ATD both decreased energy
and calmness (VAS). APTD and ATD
decreased mood after a stress task
(POMS). ATD increased anger after
stress; APTD increased boredom
before and after stress
TYR/LNAA: 79.3 PHE/LNAA:
88.6
Leyton et al124 N¼39 female social drinkers (411
consumptions/week), screened for
psychiatric family history. Between SS
design: 86.0 g placebo (n¼13)/APTD
(n¼12)/ATD (n¼14)
76.4 52.6 APTD decreased voluntary alcohol
consumption in a ‘free choice’ test.
No effect of APTD on liking of alcohol
Harmer et al122 N¼12 (7 males). No personal history of
psychiatric illness. Within SS design:
APTD (90 g)/placebo (115 g). Essential
amino acids only
87 Not reported APTD increased prolactin levels.
APTD impaired spatial working
memory and recognition memory and
increased feelings of ‘less good’. No
effect
(TYRþPHE)/LNAA: 99
Coupland et al127 N¼5 (5 males). No history of psychiatric
illness. Within SS design:
APTDþpentagastrin/placeboþplacebo/
placeboþpentagastrin
Not reported Not reported Pentagastrin increased anxiety; APTD
did not change this effect
Grevet et al123 N¼10 (10 males), 6 with a positive family
history of mental disorders. Within SS
design: 100 g APTD/placebo
56 11 APTD increased anxiety (POMS) and
tended to increase hostility. APTD
decreased the delayed word
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recognition of words. No effect on
figures or attention. No effect of
family history
McTavish et al117 N¼16 (8 males). Within SS design: 90 g
APTDþ D-amphetamine/115 g
placeboþD-amphetamine. Essential
amino acids only
65 Not reported APTD increased prolactin levels
Ratio (TYRþPHE)/LNAA: 95 No mood effects after APTD alone.
APTD reduced the psychostimulant
effects of methamphetamine (VAS
scales/cognitive tests)
N¼2 10 manic patients (8 males).
Antipsychotic medication (n¼20). Mood
stabilizers (n¼3).Between SS design: 90 g
APTD/115.0 g placebo
Not reported Not reported Decrease in manic symptoms after
APTD (35%)
Gijsman et al14 N¼12 (7 males). Within SS design: 10/30/
60 g amino acids (valine, isoleucine and
leucine)
68 (10 g) 47 (10 g) APTD increased prolactin levels after
60 g. Decreased TRP levels80 (30 g) 73 (30 g)
85 (60 g) 75 (60 g) No mood effects
Ratio (TYRþPHE)/BCAA: 12.0 (10 g), 94.6
(30 g), 96.5 (60 g)
Increased reaction times on a spatial
memory task after the 30 and 60 g
mixture
Harrison et al130 N¼13 (0 males), screened for positive
family history. Within SS design: 86 g
placebo/APTD/ATD
63.9 78.7 No effect of APTD and ATD on IL-6.
Increased fatigue scores after ATD, no
other mood effects. No effect on mood
after APTD
aEstimated.TYR: tyrosine; PHE: phenylalanine; BCAA: branch chain amino acids; LNAA: large neutral amino acids.
Table 2 Continued
References Population, design % reduction after APTD Main findings
Tyrosine Phenylalanine
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formation of crystals in urine,81 although probably
only if individuals do not drink enough water.
Another more practical point of concern is that the
procedure is very time consuming. Finally, it is not
quite clear as to what extent the AMPT procedure
affects NE and DA. This will be further discussed
below. Analogous to the development of Trp-free
mixtures instead of PCPA, tyrosine/phenylalanine-
free mixtures are now increasingly replacing AMPT.
Acute phenylalanine/tyrosine depletion
Mechanisms and procedure The synthesis of CAs
can be influenced by deprivation of the precursor
AAs, phenylalanine and tyrosine. APTD parallels the
ATD paradigm, except that individuals ingest an AA
mixture that lacks tyrosine and its precursor
phenylalanine. The mixture stimulates protein
synthesis, consuming circulating tyrosine and
phenylalanine and rendering less of these available
for transport to the brain. Furthermore, phenylalanine
and tyrosine compete with other LNAAs (Trp,
leucine, isoleucine and valine) at a relative
disadvantage to cross the blood–brain barrier.113
Placebo testing usually consists of a balanced
mixture containing all (essential) AAs (Table 2).
Animal studies have shown that a tyrosine/pheny-
lalanine-free mixture reduces levels of tyrosine and of
the DA metabolites HVA and 3,4-dihydroxyphenyla-
cetic in the caudate nucleus of the rat brain, but does
not alter DA levels themselves.113 In monkeys, APTD
reduces plasma tyrosine levels, CSF-, MHPG- and
HVA-levels in similar ways as ATD affects plasma
TRP- and CSF 5-HIAA levels.114 Ingestion of a
tyrosine/phenylalanine-free mixture has also been
associated with a reduction of the tyrosine hydro-
xylase rate.115 In monkeys which voluntarily consume
moderate or high levels of alcohol, APTD has been
associated with reduced alcohol intake, whereas no
behavioral effects were observed after ingestion of a
balanced or tryptophan-free mixture.114
Effect of APTD on plasma levels in humans In one of
the first studies in humans, five healthy males had
two different strengths of a tyrosine/phenylalanine-
free mixture (15.75 and 31.5 g essential AA), a control
drink (including tyrosine and phenylalanine) and a
fasting period.116 The results suggested a dose–
response relationship; 6 h after ingestion of the
31.5 g AA mixture, plasma tyrosine and
phenylalanine levels were maximally reduced to
12.7 and 29.8% of the initial value. The 15.75 g AA
mixture reduced plasma tyrosine and phenylalanine
levels to 61.7 and 59.7%, whereas nonsignificant
changes in plasma levels were observed after the
control mixture and in the fasting condition.
Although the exact composition and amount of AAs
have varied, the minimum levels of 10–30% of initial
plasma baseline values after APTD have been
replicated.117–119 This suggests a nonlinear dose–
response relationship, with plasma CA precursor
levels being maximally reduced after ingestion of at
least a 30 g tyrosine/phenylalanine-free mixture.
However, plasma tyrosine and phenylalanine were
Table 3 Composition of the amino-acid mixtures in APTD studies
Amino acidsa (a) (b) (c) (d) (e)
L-Alanine 5.6
L-Arginine 4.9
L-Cysteine 2.7
L-Histidine 3.2
L-Phenylalanine
L-Isoleucine 13.3 16.6 16.6 8.0 30
L-Leucine 21.0 25 25 13.5 40
L-Threonine 9.5 11.1 11.1 6.9
L-Methionine 21.0 5.6 5.6 3.0
L-Proline 12.2
L-Serine 6.9
L–Lysine (HCL) 15.2 19.4 19.4 11.0
L–Tyrosine
L-Valine 15.2 19.4 19.4 8.9 30
Glycine 3.2
L-Tryptophan 4.8 2.8 2.8 2.3
Total amountb
Active mixture (g) 15.75 45.0 90.0 100.0 30.0
31.5 57.5 60.0
Control mixture (g) 115.0 10.0
aAmino acids expressed as a percentage from the total amount of tyrosine/phenylalanine-free amino-acid mixture. bTotal
amount reduced by 15–20% in women. (a) Moja et al.116 (b) Sheehan et al.120 (c) McTavish et al;125,117 Harmer et al.122
(d) Leyton et al;118,119,124 Coupland et al;127 Harrison et al;130 Grevet et al.123 (e) Gijsman et al.14
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only moderately reduced to 50 and 40% of baseline
values in a study that used a 45.0 g tyrosine/
phenylalanine-free mixture of seven essential
AAs.120 As noted by the authors, these relatively
moderate reductions may be related to the absence of
an overnight fast prior to AA administration.
Moreover, APTD was started in the late afternoon,
whereas other studies usually start in the morning.
Since there is evidence for diurnal variation of plasma
AA levels,121 this may have influenced the results. A
30 or 60 g mixture of branch chain AAs (isoleucine,
valine, leucine) also reduced tyrosine levels by about
70%, but Trp levels were also decreased.14
To summarize, animal and human studies have
shown that ingestion of a tyrosine/phenylalanine-free
mixture temporarily reduces plasma tyrosine and
phenylalanine levels within a 7 h time interval. The
compositions of the AA mixture are more variable
between studies than is the case for ATD (see Table 3).
There may be a dose–response relationship, rendering
it a promising method to investigate CA function
experimentally.
Behavioral effects of APTD In healthy individuals,
APTD does not induce depressive symptoms, as
measured with the Hamilton scale. Unlike ATD,
self-report ratings of depressed mood are also
unaffected by APTD,118,119,122,123 except when it is
followed by a public speaking task.118,119 Slight
increases have been observed in ‘anger’, ‘tension’ or
‘boredom’ ratings using visual analogue scales;
however, these findings are not consistent.118,119,123
As had been observed in monkeys, APTD but not
ATD decreased voluntary alcohol ingestion (using a
free choice ‘taste’ test) in healthy female social
drinkers.124 APTD also reduced the psychostimulant
effects of amphetamine (indicated by self-report and
by cognitive tests),125,126 but did not influence
pentagastrin-induced anxiety.127 In addition, cogni-
tive processes are affected by APTD. Some studies
suggest that APTD specifically interferes with spatial
short-term and working memory, while it has no effect
on sustained attention or other memory pro-
cesses.14,122 However, another study found an impair-
ment in the retrieval of words from long-term
memory, whereas attention and memory for abstract
figures remained unchanged.123
A recent study compared the cognitive effects of
ATD and APTD in a double-blind, placebo-controlled
crossover study in healthy volunteers. ATD selec-
tively impaired memory consolidation, whereas
APTD selectively impaired working memory perfor-
mance.128 A small study found that APTD did not
induce changes in PET Raclopride D2 binding.129
Prolactin levels are increased after APTD,14,126 which
is indicative of reduced central DA brain function.
Secretion of melatonin levels remained unaffected by
APTD,120 nor does APTD affect immunological para-
meters (IL-6).130 In a sample of 20 bipolar patients
(acute manic phase), APTD was associated with a
35% decrease in manic symptoms.117 No studies were
found that investigated the effects in depressed
patients or in other clinical samples.
To summarize, APTD does not induce significant
mood changes in healthy individuals, although mood
changes may occur if APTD is combined with
experimental stress induction. Some studies ex-
cluded individuals with a psychiatric family history
or included only women or only men,118,119,130 but
there is no evidence that factors like gender or family
history could fully explain the inconsistent findings
on mood. Cognitive effects may be more common in
healthy samples, but again the results are not
consistent. Methodological factors including the use
of different AA mixtures, measurement instruments
and investigated population may explain these
differences.
Discussion
An overview of the main findings is presented in
Table 4. The evidence suggests that all three inter-
ventions are neurochemically specific, in terms of
their short-term effects on one or two neurotransmit-
ter systems, rather than on brain protein metabolism
in general. The AMPT procedure is somewhat less
selective, affecting both the DA and NE systems. The
behavioral effects of ATD and AMPT are remarkably
similar. Neither procedure has an immediate effect on
the symptoms of depressed patients, and both have an
effect on recently recovered depressed patients,
which is influenced by prior treatment: ATD affects
a subgroup of SSRI-treated patients, whereas AMPT
affects a subgroup of NRI-treated patients. Remission
of SAD (both after light treatment and natural summer
remission) is temporarily reversed by both ATD
and AMPT. The response of patients who recovered
on dual-acting medications (clomipramine or high-
dose venlafaxine) has not been systematically inves-
tigated.
Patients who have been in remission for longer may
also be vulnerable to ATD and AMPT. However, the
relationship with prior treatment is much weaker. For
these patients, individual vulnerability markers (such
as chronicity, gender, history of suicidality, family
history of psychiatric illness or genetic variability) are
probably the more important predictors of depressive
response to challenge procedures. These challenges
are therefore not only useful to investigate the
mechanism of action of antidepressants, but also as
models of vulnerability to depression.
The rarity of placebo responses to each of the
procedures is striking. Since the procedures are rather
burdensome (in terms of time investment, side effects,
expectancy of mood effects), one might expect high
rates of negative mood during control sessions also,
but that is not the case.
Despite the similarities, specific effects of 5-HT vs
CA depletions do exist. The best examples of this are
the dependency on prior treatment in recovered
patients and the distinctive effects of ATD and APTD
on different memory systems. A memory consolida-
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Table 4 Comparison of the effects of ATD, AMPT and APTD
ATD AMPT APTD
Biochemical effects
Magnitude of reduction
of precursor levels
70–90% (NB: plasma Trp/
LNAA ratio better estimate
of central effects than Trp
(free/total))
Unknown 70–85% (tyrosine)
50% (phenylalanine)
Dose–response relationship Probably nonlinear Unknown Probably nonlinear
Time course of reduction
(maximum effect)
5–7 h after depletion 24–48 h after
starting treatment
5–7 h after depletion
Decrease in metabolite
levels (%)
CSF 5-HIAA 34
HVA 60–80 27.4
MHPG 50–60 26.9
Mood effects
Depression
Medication-free,
symptomatic patients
No direct effect. Delayed
effect (bidirectional) in
some patients
No effect on mood Unknown
Recently remitted, medicated
patients
Lowered mood. 50–60%
relapse. Treatment-specific
(SSRI)
Lowered mood. 50–60%
relapsed. Treatment-specific
(NRI)
Unknown
Recovered depressed patients Lowered mood. Partial
relapse 40–50%. Full
relapse rare. Predictors:
chronicity, female gender,
history of suicidality
Lowered mood. Relapse rate:
76%
Unknown
SAD patients
Recently remitted from light
therapy
Lowered mood Lowered mood Unknown
Summer remission Lowered mood. Response to
ATD predicts depression
during next winter
Lowered mood Unknown
Bipolar disorder patients
In remission, stable at lithium No effect Delayed effect on hypomanic
symptoms
Unknown
Other mental disorders
OCD, unmedicated No effect on OCD
symptoms or mood
No effect on OCD symptoms
or mood
Unknown
Schizophrenia No effect on symptoms Improvement of positive
symptoms
Unknown
Cocaine users Decreased feelings of ‘high’ Decreased feelings of ‘high’ Unknown
Bulimia nervosa Small effect on mood
and desire to binge
Unknown Unknown
Panic disorder Increases vulnerability to CO2
and flumazenil challenge
Unknown Unknown
Healthy volunteers
Mood Small mood changes in
vulnerable individuals.
No ‘depression’
Small mood changes in some
individuals. No ‘depression’
Small mood changes in some
individuals. No ‘depression’
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tion deficit was induced by ATD and not by APTD,
whereas a working memory deficit was induced
by APTD and not ATD.128 These findings are in
accordance with the effects of 5-HT and DA
enhancement,12 which consisted of opposing influ-
ences on working memory. The effects of DA
enhancement were positive, consistent with a posi-
tive linear association of DA and working memory
performance. As for 5-HT, there was no association at
low levels, whereas high levels impair working
memory, possibly by interfering with DA neurotrans-
mission. However, the observed improvement of
focused attention after ATD may reflect improved
working memory functions at low levels of 5-HT,
which would again be in line with the known
opposing influences of 5-HT and DA on working
memory in the frontal cortex.12,70 The specific
memory consolidation deficit after ATD must then
be based on a different mechanism. It has previously
been suggested, on the basis of observations in ATD
effects on regional lowering of 5-HT in the brain in
animals, that this effect is specifically linked with low
5-HT induced disruption of hippocampal function.23
The putative negative linear association of memory
consolidation with 5-HT functioning predicts im-
proved memory consolidation after 5-HT augmenta-
tion. This could be obscured at higher levels of 5-HT
because working memory impairments automatically
affect performance on long-term memory tasks.
Further illustrations of selective neurochemical and
clinical effects may be the association of ATD with
appetite, especially in bulimia patients. The absence
of DA effects on appetite remains to be demonstrated,
however. Conversely, the review provides evidence
for the specific association of DA and addictive/
rewarding behaviors, whereas strong evidence for an
association with 5-HT is lacking.
As for hormonal markers of 5-HT and DA manip-
ulations, the available evidence seems to confirm that
5-HT and cortisol are positively associated, whereas
DA and Prl are specifically negatively associated.
Their combined use therefore would enable a ‘read-
out’ of 5-HT/DA balance. However, it should be
remembered that cortisol is a sensitive indicator of
Other effects
Cognition Impaired memory
consolidation. Possible effect
on working memory. Possibly
improved attention. Effect on
executive function (planning)
depends on sample (no effect
in normals)
Impaired attention, possibly
due to sedation
Impaired spatial short-term
and working memory
Immune system Unknown No effect on IL-6
Food/drink choices No effect on alcohol intake or
craving in alcoholics. Small
increase of protein intake
Unknown Decreased alcohol intake
Sleep Decreased REM sleep.
Inconsistent effect on other
sleep measures
Decreased sleep latency.
Sleepiness. Insomnia after
stopping AMPT
Unknown
Melatonin Decreased nocturnal
melatonin secretion
Decreased melatonin
secretion
No effect on melatonin
Prolactin No effect Increased Increased
Receptor binding Decreased 5-HT2 receptor
density
Increased D2 receptor binding Unknown
Methodological factors
Specificity 5-HT NA and DA Mainly DA?
Response to ‘placebo’ testing Mood effects very rare. NB:
different biochemical effects
of different ‘placebo’
procedures
Mood effects very rare Mood effects very rare
See also Van der Does5 for a more detailed overview of ATD studies up to July 1999.
Table 4 Continued
ATD AMPT APTD
Monoamine depletion review
L Booij et al
968
Molecular Psychiatry
5-HT augmentation rather than of 5-HT lowering.
Furthermore, cortisol is a nonspecific indicator of
HPA-axis activity, and there are many other neuro-
chemical and physiological influences contributing to
acute cortisol release. Finally, transient depressive
symptoms in healthy samples seem to be more
prominently induced by ATD than by APTD and
AMPT, although AMPT may be sedative. Possibly this
latter effect is specifically noradrenergically
mediated.
A major methodological concern is the specificity
of AMPT and APTD. It is not clear to what extent the
effects are mediated by NE and DA brain function.
There are reasons to suggest that AMPT affects DA
and NE, whereas APTD mainly affects DA. In rats,
administration of AMPT decreased baseline
extracellular NE and inhibited the idaxozan-induced
increase in extracellular NE activity.131 After APTD,
baseline NE levels remained unchanged and APTD
could not change the idazoxan-evoked increase in NE
levels.131 Moreover, since APTD in humans did not
attenuate the amphetamine-induced decreases of
hunger or response sensitivity on a sustained atten-
tion task, these behaviors may largely be mediated
by the NE rather than the DA system.125 This may also
be true for the reduced alcohol intake found in
animals and humans.114,124 AMPT and APTD both
increased Prl levels, indicative of reduced DA func-
tion. Finally, human plasma melatonin levels, indir-
ect indicators of central NE synthesis, are reduced
after AMPT,106 but not after APTD.120 It should be
noted, however, that the moderate reduction of
plasma levels in the latter study may have influenced
the results.
A limited number of studies compared the effects
of APTD with ATD in the same individuals,
which prevents inconsistencies due to chance varia-
tions between samples. Another argument for incor-
porating an active control condition is that comparing
two active conditions and placebo requires only
1.5 times more data than one active condition
and placebo. In other words, combining ATD vs
placebo and APTD vs placebo experiments would
save many placebo sessions and would increase
scientific value in terms of specificity of the mechan-
isms of the experimental manipulation of monoamine
function. An important caveat, however, is that the
test–retest reliability of most challenges is completely
unknown, as well as possible carryover or order
effects.
The findings presented in Table 4 concerning
the ‘other psychiatric disorders’ should be viewed
with caution (particularly the AMPT and APTD
findings) since some of these are based on only one
study. The more detailed findings are described in the
text and in Tables 1 and 2. The clinical significance of
response to monoamine depletion procedures is a
potentially fruitful area for research, since some
encouraging data exist for ATD.26,52 An area that
remains completely unexplored is the relationship
between these biological indices of depression
vulnerability with psychological vulnerability
measures. Recent research based on Beck’s cognitive
model of depression132 has yielded a new measure of
vulnerability, labeled cognitive reactivity (CR).133
Research has shown that CR is higher in previously
depressed but euthymic individuals than in never-
depressed individuals.134–136 Furthermore, CR is high-
er in remitted patients who were treated with
medication than in those treated with cognitive
therapy. The same study found that CR predicts
future depressive episodes, irrespective of prior
treatment.136 It would be interesting to know how
different biological and psychological treatments
affect biological and psychological vulnerabilities,
and whether and how these two types of vulnerability
are related.
Acknowledgements
The Netherlands Organization of Sciences–Medical
Sciences (NWO-MW) Grant 903-57-132 to Dr Van der
Does facilitated the preparation of this paper.
References
1 Blier P, De Montigny C. Possible serotonergic mechanisms
underlying the antidepressant and anti-obsessive–compulsive
disorder responses. Biol Psychiatry 1998; 44: 313–323.
2 Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J et al.
Mechanisms of action of selective serotonin reuptake inhibitors
in the treatment of psychiatric disorders. Eur Neuropsychophar-
macol 1999; 9: S81–S86.
3 Young SN, Smith S, Pihl RO, Ervin FR. Tryptophan depletion
causes a rapid lowering of mood in normal males. Psychophar-
macology 1985; 87: 173–177.
4 Reilly JG, McTavish SFB, Young AH. Rapid depletion of plasma
tryptophan. J Psychopharmacol 1997; 11: 381–392.
5 Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK,
Heninger GR et al. Serotonin and the neurobiology of depression.
Arch Gen Psychiatry 1994; 51: 865–874.
6 Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN.
Mood-lowering effect of tryptophan depletion. Enhanced sus-
ceptibility in young men at genetic risk for major affective
disorders. Arch Gen Psychiatry 1994; 51: 687–697.
7 Van Praag HM, Asnis GM, Kahn RS, Brown SL, Korn M,
Friedman JM et al. Nosological tunnel vision in biological
psychiatry. A plea for a functional psychopathology. Ann NY
Acad Sci 1990; 600: 501–510.
8 Stahl SM. Mechanism of action of serotonin selective
reuptake inhibitors. Serotonin receptors and pathways mediate
therapeutic effects and side effects. J Affect Disord 1998; 51:
215–235.
9 Van Praag HM. Faulty cortisol/serotonin interplay: psychopatho-
logical and biological characterisation of a new, hypothetical
depression subtype (seca depression). Psychiatry Res 1996; 65:
143–157.
10 Riedel WJ, Schoenmakers E, Vermeeren A, O’Hanlon JF. The
influence of trazodone treatment on cognitive functions in
outpatients with major depressive disorder. Hum Psychophar-
macol 1999; 14: 499–508.
11 Robbins TW, Everitt BJ. Limbic-striatal memory systems and drug
addiction. Neurobiol Learn Mem 2002; 78: 625–636.
12 Luciana M, Collins PF, Depue RA. Opposing roles for dopamine
and serotonin in the modulation of human spatial working
memory functions. Cereb Cortex 2002; 8: 218–226.
13 Cahill L, Prins B, Weber M, McGaugh JL. Beta-adrenergic
activation and memory for emotional events. Nature 1994; 371:
702–704.
Monoamine depletion review
L Booij et al
969
Molecular Psychiatry
14 Gijsman HJ, Scarna A, Harmer CJ, McTavish SB, Odontiadis J,
Cowen PJ et al. A dose-finding study on the effects of branch
chain amino acids on surrogate markers of brain dopamine
function. Psychopharmacology (Berl) 2002; 160: 192–197.
15 Van der Does AJW. The effects of tryptophan depletion on
mood and psychiatric symptoms. J Affect Disord 2001; 64: 107–
119.
16 Carpenter LL, Anderson GM, Pelton GH, Guding JA, Kirwin PD,
Price LH et al. Tryptophan depletion during continuous CSF
sampling in healthy human subjects. Neuropsychopharmacology
1997; 19: 26–35.
17 Krahn LE, Lu PY, Klee G, Delgado PL, Lin SC, Zimmerman RC.
Examining serotonin function: a modified technique for rapid
tryptophan depletion. Neuropsychopharmacology 1996; 15: 325–
328.
18 Weltzin TE, Fernstrom JD, McConaha C, Kaye WH. Acute
tryptophan depletion in bulimia: effects on large neutral amino
acids. Biol Psychiatry 1994; 35: 388–397.
19 Wolfe BE, Metzger ED, Jimerson DC. Comparison of the effects of
amino acid mixture and placebo on plasma tryptophan to large
neutral amino acid ratio. Life Sci 1995; 56: 1395–1400.
20 Booij L, Van der Does AJW, Benkelfat C, Bremner JD, Cowen PJ,
Fava M et al. Predictors of mood response to acute tryptophan
depletion: a reanalysis. Neuropsychopharmacology 2002; 27:
852–861.
21 Blokland A, Lieben CKJ, Van Oorsouw KIM, Deutz NEP. A new
method for lowering plasma tryptophan concentrations: no effect
on affective behavior but impaired object memory in rats. Soc
Neurosci Abstr 2001; 319.1.
22 Lieben CKJ, Westerink B, Blokland A, Deutz NEP. Acute
tryptophan and serotonin depletion using an optimized trypto-
phan-free protein-carbohydrate mixture in the adult rat. Neuro-
chem Int 2004; 44: 9–16.
23 Blokland A, Lieben C, Deutz NEP. Anxiogenic and depressive-
like effects, but no cognitive deficits after repeated moderate
tryptophan depletion in the rat. J Psychopharmacol 2002; 16: 39–
49.
24 Brown CM, Fletcher PJ, Coscina DV. Acute amino acid loads that
deplete brain serotonin fail to alter behavior. Pharmacol Biochem
Behav 1998; 59: 115–121.
25 Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight
KM, Allen J et al. Tryptophan depletion and depressive
vulnerability. Biol Psychiatry 1999; 46: 498–505.
26 Moreno FA, Heninger GR, McGahuey CA, Delgado PL. Trypto-
phan depletion and risk of depressive relapse. Biol Psychiatry
2000; 48: 327–329.
27 Leyton M, Ghadirian AM, Young SN, Palmour RM, Blier P,
Helmers KF et al. Depressive relapse following acute tryptophan
depletion in patients with major depressive disorder. J Psycho-
pharmacol 2000; 14: 84–287.
28 Spillmann MK, Van der Does AJW, Rankin M, Vuolo R, Alpert JF,
Nierenberg AA et al. Tryptophan depletion in SSRI-recovered
depressed outpatients. Psychopharmacology 2001; 155:
123–127.
29 Johnson L, El-Khoury A, Aberg-Wistedt A, Stain-Malmgren R,
Mathe AA. Tryptophan depletion in lithium-stabilized patients
with affective disorder. Int J Neuropsychopharmacol 2001; 4:
329–336.
30 Hughes JH, Dunne F, Young AH. Effects of acute tryptophan
depletion on mood and suicidal ideation in bipolar patients
symptomatically stable on lithium. Br J Psychiatry 2000; 177:
447–451.
31 Benkelfat C, Seletti B, Palmour RM, Hillel J, Ellenbogen M, Young
SN. Tryptophan depletion in stable lithium-treated patients with
bipolar disorder in remission. Arch Gen Psychiatry 1995; 52:
154–155.
32 Cassidy F, Murray E, Carroll BJ. Tryptophan depletion in recently
manic patients treated with lithium. Biol Psychiatry 1998; 43:
230–232.
33 Leyton M, Young SN, Benkelfat C. Relapse of depression after
rapid depletion of tryptophan. Lancet 1997; 349: 1840–1841.
34 Van der Does AJW. The mood-lowering effect of tryptophan
depletion: possible explanation for discrepant findings. Arch Gen
Psychiatry 2001; 58: 200–201.
35 Delgado PL, Charney DS, Price LH, Aghajanian G, Landis H,
Heninger GR. Serotonin function and the mechanism of
antidepressant action. Arch Gen Psychiatry 1990; 47: 411–
418.
36 Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal
JH et al. Rapid serotonin depletion as a provocative challenge test
for patients with major depression. Psychopharmacol Bull 1991;
27: 321–330.
37 Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH,
Moreno FA et al. Tryptophan-depletion challenge in depressed
patients treated with desipramine or fluoxetine. Biol Psychiatry
1999; 46: 212–220.
38 Yatham LN, Liddle PF, Shiah IS, Lam RW, Adam MJ et al. Effects
of rapid tryptophan depletion on brain 5-HT2 receptors: a PET
study. Br J Psychiatry 2001; 178: 448–453.
39 Price LH, Malison RT, McDougle CJ, Pelton GH, Heninger GR.
The neurobiology of tryptophan depletion in depression: effects
of intravenous tryptophan infusion. Biol-Psychiatry 1998; 43:
339–347.
40 Van Praag HM. Serotonin related, anxiety/aggression driven,
stressor precipitated depression: a psycho biological hypothesis.
Eur Psychiatry 1996; 11: 57–67.
41 Riedel WJ, Sobczak S, Nicolson N, Honig A. Stress,cortisol and
memory as markers of serotonergic vulnerability. Acta Neurop-
sychiatr 2002; 14: 186–191.
42 Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J
et al. Association between a serotonin transporter promoter
region polymorphism and mood response during tryptophan
depletion. Mol Psychiatry 2002; 7: 213–216.
43 Neumeister A, Konstantinidis A, Stastny J, Schwarz MJ,
Vitouch O, Willeit M et al. Association between serotonin
transporter gene promoter polymorphism (5HTTLPR) and beha-
vioral responses to tryptophan depletion in healthy women with
and without family history of depression. Arch Gen Psychiatry
2002; 59: 613–620.
44 Van der Does AJW. The mood-lowering effect of tryptophan
depletion: possible explanation for discrepant findings [Letter].
Arch Gen Psychiatry 2001; 58: 200–201.
45 Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME. 5-
HT1A receptor function in normal subjects on clinical doses of
fluoxetine: blunted temperature and hormone responses to
ipsapirone challenge. Neuropsychopharmacology 1999; 20:
628–639.
46 Quested DJ, Sargent PA, Cowen PJ. SSRI treatment decreases
prolactin and hyperthermic responses to mCPP. Psychopharma-
cology 1997; 133: 305–308.
47 Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C.
Acute tryptophan depletion in healthy young women with a
family history of major affective disorder. Psychol Med 1999; 29:
35–46.
48 Quintin P, Benkelfat C, Launay JM, Arnulf I, Pointereau-
Bellenger A, Barbault S et al. Clinical and neurochemical
effect of acute tryptophan depletion in unaffected relatives of
patients with bipolar affective disorder. Biol Psychiatry 2001; 50:
184–190.
49 Klaassen T, Riedel WJ, Deutz NEP, Van Praag HM. Mood
congruent memory bias induced by tryptophan depletion.
Psychol Med 2002; 32: 167–172.
50 Sobczak S, Honig A, Nicolson NA, Riedel WJ. Effects of
acute tryptophan depletion on mood and cortisol release in
first-degree relatives of type I and type II bipolar patients and
healthy matched controls. Neuropsychopharmacology 2002; 27:
834–842.
51 Stewart ME, Deary IJ, Ebmeier KP. Neuroticism as a predictor of
mood change: the effects of tryptophan depletion. Br J Psychiatry
2002; 181: 242–247.
52 Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O,
Rauh M, Barochka A et al. Effects of tryptophan depletion in fully
remitted patients with seasonal affective disorder during sum-
mer. Psychol Med 1998; 28: 257–264.
53 Lam RW, Bowering TA, Tam EM, Grewal A, Yatham LN, Shiah IS
et al. Effects of rapid tryptophan depletion in patients with
seasonal affective disorder in natural summer remission. Psychol
Med 2000; 30: 79–87.
Monoamine depletion review
L Booij et al
970
Molecular Psychiatry
54 Bell C, Abrams J, Nutt D. Tryptophan depletion: implications for
psychiatry. Br J Psychiatry 2001; 178: 399–405.
55 Neumeister A, Konstantinidis A, Praschak-Rieder N, Willeit M,
Hilger E, Stastny J et al. Monoaminergic function in the
pathogenesis of seasonal affective disorder. Int J Neuropsycho-
pharmacol 2001; 4: 409–420.
56 Van der Does AJW. Acute tryptophan depletion (ATD) induces
depressive symptoms [Letter]. Psychol Med 2003; 33:
1133–1134.
57 Kaye WH, Gendall KA, Fernstrom MH, Fernstrom JD, McConaha
CW, Weltzin TE. Effects of acute tryptophan depletion on mood
in bulimia nervosa. Biol Psychiatry 2000; 47: 151–157.
58 Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S
et al. Does 5-HT restrain panic? J Psychopharmacol 2002; 16:
5–14.
59 Miller HEJ, Deakin JFW, Anderson IM. Effect of acute tryptophan
depletion on CO2-induced anxiety in patients with panic
disorder and normal volunteers. Br J Psychiatry 2000; 176:
182–188.
60 Schruers K, Klaassen T, Pols H, Overbeek T, Deutz NEP, Griez E.
Effects of tryptophan depletion on carbon dioxide provoked
panic in panic disorder patients. Psychiatry Res 2000; 93: 179–
187.
61 Petrakis IL, Buonopane A, O’Malley S, Cermik O, Trevisan L,
Boutros NN et al. The effect of tryptophan depletion on alcohol
self-administration in non-treatment-seeking alcoholic indivi-
duals. Alcohol Clin Exp Res 2002; 26: 969–975.
62 Petrakis IL, Trevisan L, Boutros NN, Limoncelli D, Cooney NL,
Krystal JH. Effect of tryptophan depletion on alcohol cue-induced
craving in abstinent alcoholic patients. Alcohol Clin Exp Res
2001; 25: 1151–1155.
63 Crean J, Richards JB, De Wit H. Effect of tryptophan depletion on
impulsive behavior in men with or without a family history of
alcoholism. Behav Brain Res 2002; 136: 349–357.
64 Golightly KL, Lloyd JA, Hobson JE, Gallagher P, Mercer G, Young
AH. Acute tryptophan depletion in schizophrenia. Psychol Med
2001; 31: 75–84.
65 Bjork JM, Dougherty DM, Moeller FG, Swann AC. Differential
behavioral effects of plasma tryptophan depletion and loading in
aggressive and nonaggressive men. Neuropsychopharmacology
2000; 22: 357–369.
66 Bond AJ, Wingrove J, Critchlow DG. Tryptophan depletion
increases aggression in women during the premenstrual phase.
Psychopharmacology 2001; 156: 477–480.
67 Schmeck K, Sadigorsky S, Englert E, Demisch L, Dierks T, Barta S
et al. Mood changes following acute tryptophan depletion in
healthy adults. Psychopathology 2002; 35: 234–240.
68 Marsh DM, Dougherty DM, Moeller FG, Swann AC, Spiga R.
Laboratory-measured aggressive behavior of women: acute tryp-
tophan depletion and augmentation. Neuropsychopharmacology
2002; 26: 660–671.
69 Cleare AJ, Bond AJ. The effect of tryptophan depletion and
enhancement on subjective and behavioural aggression in normal
male subjects. Psychopharmacology 1995; 118: 72–81.
70 Schmitt JAJ, Jorissen BL, Sobczak S, Van Boxtel MPJ, Hogervorst
E, Deutz NEP et al. Tryptophan depletion impairs memory
consolidation, but improves focused attention in healthy young
volunteers. J Psychopharmacol 2000; 14: 21–29.
71 Riedel WJ, Klaassen T, Deutz NEP, Van Someren A, Van Praag
HM. Tryptophan depletion in normal volunteers produces
selective impairment in memory consolidation. Psychopharma-
cology 1999; 141: 362–369.
72 Sobczak S, Riedel WJ, Booij L, Aan het Rot M, Deutz NEP, Honig
A. Cognition following acute tryptophan depletion: difference
between first-degree relatives of bipolar disorder patients and
matched healthy control volunteers. Psychol Med 2002; 32:
503–515.
73 Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ. The
effects of tryptophan depletion on cognitive and affective
processing in healthy volunteers. Psychopharmacology 2002;
163: 42–53.
74 Hughes JH, Gallagher P, Young AH. Effects of acute tryptophan
depletion on cognitive function in euthymic bipolar patients. Eur
Neuropsychopharmacol 2002; 12: 123–128.
75 Porter RJ, Lunn BS, Walker LLM, Gray JM, Ballard CG, O’Brien JT.
Cognitive deficit induced by acute tryptophan depletion in
patients with Alzheimer’s disease. Am J Psychiatry 2000; 157:
638–640.
76 Porter RJ, Marshall EF, O’Brien JT. Effects of rapid
tryptophan depletion on salivary and plasma cortisol in Alzhei-
mer’s disease and the healthy elderly. J Psychopharmacol 2002;
16: 73–78.
77 Sjoerdsma A, Engelman K, Spector S. Inhibition of catecholamine
synthesis in man with a-methyl-paratyrosine, an inhibitor of
tyrosine hydroxylase. Lancet 1965; 2: 1092–1094.
78 Brodie HK, Murphy DL, Goodwin FK, Bunney WE. Catechola-
mines and mania: the effect of alpha-methyl-para-tyrosine on
manic behavior and catecholamine metabolism. Clin Pharmacol
Ther 1971; 12: 218–224.
79 Engelman K, Horwitz D, Jequier E, Sjoerdsma A. Biochemical and
pharmacologic effects of alpha-methyltyrosine in man. J Clin
Invest 1968; 47: 979–986.
80 Bunney WE, Brodie HKH, Murphy DL, Goodwin FK. Studies of
alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depres-
sion and mania. Am J Psychiatry 1971; 127: 872–881.
81 Brogden RN, Heel RC, Speight TM, Avery GS. Alpha-methyl-
p-tyrosine: a review of its pharmacology and clinical use. Drugs
1981; 21: 81–89.
82 Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S. Use of
synthesis inhibitors in defining a role for biogenic amines during
imipramine treatment in depressed patients. Psychopharmacol
Commun 1975; 1: 239–249.
83 Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR,
Gelenberg AJ et al. Monoamines and the mechanism of
antidepressant action: effects of catecholamine depletion on
mood of patients treated with antidepressants. Psychopharmacol
Bull 1993; 29: 389–396.
84 Krahn LE, Lin SC, Klee GG, Lu PY, Ory SJ, Zimmermann RC.
The effect of presynaptic catecholamine depletion on 6-
hydroxymelatonin sulfate: a double blind study of alpha-
methyl-para-tyrosine. Eur Neuropsychopharmacol 1999; 9:
61–66.
85 Miller HL, Delgado PL, Salomon RM, Heninger GR, Charney DS.
Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free
depressed patients. Neuropsychopharmacology 1996; 14:
151–157.
86 Anand A, Darnell A, Miller HL, Berman RM, Cappiello A, Oren
DA et al. Effect of catecholamine depletion on lithium-induced
long-term remission of bipolar disorder. Biol Psychiatry 1999; 45:
972–978.
87 Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH,
Heninger GR et al. Clinical and biochemical effects of catecho-
lamine depletion on antidepressant-induced remission of depres-
sion. Arch Gen Psychiatry 1996; 53: 117–128.
88 Delgado PL, Moreno FA, Onate L, Gelenberg AJ. Sequential
catecholamine and serotonin depletion in mirtazapine-treated
depressed patients. Int J Neuropsychopharmacol 2002; 5:
63–66.
89 Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A,
Oren DA et al. Transient depressive relapse induced by
catecholamine depletion: potential phenotypic vulnerability
marker? Arch Gen Psychiatry 1999; 56: 395–403.
90 Neumeister A, Turner EH, Matthews JR, Postolache TT,
Barnett RL, Rauh M et al. Effects of tryptophan depletion vs
catecholamine depletion in patients with seasonal affective
disorder in remission with light therapy. Arch Gen Psychiatry
1998; 55: 524–530.
91 Lam RW, Tam EM, Grewal A, Yatham LN. Effects of alpha-
methyl-para-tyrosine-induced catecholamine depletion in pa-
tients with seasonal affective disorder in summer remission.
Neuropsychopharmacology 2001; 25: S97–S101.
92 Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK,
Finkelstein CO et al. Monoamine depletion in unmedicated
depressed subjects. Biol Psychiatry 2002; 51: 469–473.
93 Longhurst JG, Carpenter LL, Epperson CN, Price LH, McDougle
CJ. Effects of catecholamine depletion with AMPT (alpha-methyl-
para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry
1999; 46: 573–576.
Monoamine depletion review
L Booij et al
971
Molecular Psychiatry
94 Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R,
Kegeles LS et al. Increased baseline occupancy of D2 receptors by
dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97:
7673–7675.
95 Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A et al.
Subjective effects of AMPT-induced dopamine depletion in
schizophrenia: correlation between dysphoric responses and
striatal D2 binding ratios on SPECT imaging. Neuropsychophar-
macology 2001; 25: 642–650.
96 Stine SM, Krystal JH, Petrakis IL, Jatlow PI, Heninger GR,
Kosten TR et al. Effect of alpha-methyl-para-tyrosine on
response to cocaine challenge. Biol Psychiatry 1997; 42:
181–190.
97 McCann UD, Thorne D, Hall M, Popp K, Avery W, Sing H et al.
The effects of L-dihydroxyphenylalanine on alertness and mood
in alpha-methyl-para-tyrosine-treated healthy humans. Neurop-
sychopharmacology 1995; 13: 41–52.
98 Laruelle M, D’Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ,
Fingado CL et al. Imaging D2 receptor occupancy by endogenous
dopamine in humans. Neuropsychopharmacology 1997; 17:
162–174.
99 McCann UD, Penetar DM, Shaham Y, Thorne DR, Sing HC,
Thomas ML et al. Effects of catecholamine depletion on alertness
and mood in rested and sleep-deprived normal volunteers.
Neuropsychopharmacology 1993; 8: 345–356.
100 McCann UD, Penetar DM, Belenky G. Acute dystonic reaction in
normal humans caused by catecholamine depletion. Clin Neuro-
pharmacol 1990; 13: 565–568.
101 Salomon RM, Miller HL, Krystal JH, Henninger GR, Charney DS.
Lack of behavioral effects of monoamine depletion in healthy
subjects. Biol Psychiatry 1997; 41: 58–64.
102 Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B,
Papatheodorou G et al. A simple method to measure baseline
occupancy of neostriatal dopamine D2 receptors by dopamine in
vivo in healthy subjects. Neuropsychopharmacology 2001; 25:
213–223.
103 McCann UD, Penetar DM, Shaham Y, Thorne DR, Gillin JC,
Sing HC et al. Sleep deprivation and impaired cognition. Possible
role of brain catecholamines. Biol Psychiatry 1992; 31: 1082–
1097.
104 Tychsen L, Sitaram N. Catecholamine depletion produces
irrepressible saccadic eye movements in normal humans. Ann
Neurol 1988; 25: 444–449.
105 Zimmermann RC, Krahn L, Klee G, Lu PY, Ory SJ, Lin SC.
The impact of gender on alpha-methyl-para-tyrosine
mediated changes in prolactin secretion and 6-hydroxymelatonin
sulfate excretion. Psychoneuroendocrinology 1996; 21:
469–478.
106 Zimmermann RC, Krahn L, Klee G, Delgado P, Ory SJ, Lin SC.
Inhibition of presynaptic catecholamine synthesis with alpha-
methyl-para-tyrosine attenuates nocturnal melatonin secretion in
humans. J Clin Endocrinol Metab 1994; 79: 1110–1114.
107 Zimmermann RC, Krahn L, Rahmanie N, Sauer MV. Prolonged
inhibition of presynaptic catecholamine synthesis does not alter
leptin secretion in normal-weight men and women. Hum Reprod
1998; 13: 822–825.
108 Fujita M, Verhoeff NP, Varrone A, Zoghbi SS, Baldwin RM, Jatlow
PA et al. Imaging extrastriatal dopamine D2 receptor occupancy
by endogenous dopamine in healthy humans. Eur J Pharmacol
2000; 387: 179–188.
109 Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G,
Wilson AA et al. Dopamine depletion results in increased
neostriatal D2, but not D1, receptor binding in humans. Mol
Psychiatry 2002; 7: 322–328.
110 Hindmarch I. Instrumental assessment of psychomotor functions
and the effects of psychotropic drugs. Acta Psychiatr Scand
Suppl 1994; 380: 49–52.
111 Schmitt JAJ, Ramaekers JG, Kruizinga MJ, Van Boxtel MPJ,
Vuurman EFPM, Riedel WJ. Additional dopamine reuptake
inhibition attenuates vigilance decrement induced by serotoner-
gic reuptake inhibition in man. J Psychopharmacol 2002; 16:
207–214.
112 Loubinoux I, Pariente J, Boulanouar K, Carel C, Manelfe C, Rascol
O et al. A single dose of the serotonin neurotransmission agonist
paroxetine enhances motor output: double-blind, placebo-con-
trolled, fMRI study in healthy subjects. Neuroimage 2002; 15:
26–36.
113 Biggio G, Porceddu ML, Gessa GL. Decrease of homovanillic,
dihydroxyphenylacetic acid and cyclic-adenosine-30,50-mono-
phosphate content in the rat caudate nucleus induced by
the acute administration of an aminoacid mixture lacking
tyrosine and phenylalanine. J Neurochem 1976; 26:
1253–1255.
114 Palmour RM, Ervin FR, Baker GB, Young SN. An amino acid
mixture deficient in phenylalanine and tyrosine reduces
cerebrospinal fluid catecholamine metabolites and alcohol
consumption in vervet monkeys. Psychopharmacology 1998;
136: 1–7.
115 Fernstrom MH, Fernstrom JD. Acute tyrosine depletion reduces
tyrosine hydroxylation rate in rat central nervous system. Life Sci
1995; 57: 97–102.
116 Moja EA, Lucini V, Benedetti F, Lucca A. Decrease in
plasma phenylalanine and tyrosine after phenylalanine–
tyrosine free amino acid solutions in man. Life Sci 1996; 24:
2389–2395.
117 McTavish SF, McPherson MH, Harmer CJ, Clark L, Sharp T,
Goodwin GM, Cowen PJ. Antidopaminergic effects of dietary
tyrosine depletion in healthy subjects and patients with manic
illness. Br J Psychiatry 2001; 179: 356–360.
118 Leyton M, Young SN, Blier P, Baker GB, Pihl RO, Benkelfat C. A
comparison of the effects of acute tryptophan depletion and acute
phenylalanine/tyrosine depletion in healthy women. Adv Exp
Med Biol 1999; 46: 767–771.
119 Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P
et al. Effects on mood of acute phenylalanine/tyrosine
depletion in healthy women. Neuropsychopharmacology 2000;
22: 52–63.
120 Sheehan BD, Tharyan P, McTavish SFB, Campling GM, Cowen PJ.
Use of a dietary manipulation to deplete plasma tyrosine and
phenylalanine in healthy subjects. J Psychopharmacol 1996; 10:
231–234.
121 Eriksson T, Wiesel K, Voog L, Hagman M. Diurnal rhythms in rat
plasma amino acids. Life Sci 1989; 45: 979–986.
122 Harmer CJ, McTavish SF, Clark L, Goodwinn GM, Cowen PJ.
Tyrosine depletion attenuates dopamine function in healthy
volunteers. Psychopharmacology 2001; 154: 105–111.
123 Grevet EH, Tietzmann MR, Shansis FM, Hastenpflug C, Santana
LC, Forster L et al. Behavioural effects of acute phenylalanine
and tyrosine depletion in healthy male volunteers. J Psycho-
pharmacol 2002; 16: 51–55.
124 Leyton M, Young SN, Blier P, Baker GB, Pihl RO, Benkelfat C.
Acute tyrosine depletion and alcohol ingestion in healthy
women. Alcohol Clin Exp Res 2000; 24: 459–464.
125 McTavish SFB, McPherson MH, Sharp T, Cowen PJ. Attenuation
of some subjective effects of amphetamine following tyrosine
depletion. J Psychopharmacol 1999; 13: 144–147.
126 McTavish SF, Raumann B, Cowen PJ, Sharp T. Tyrosine
depletion attenuates the behavioural stimulant effects of
amphetamine and cocaine in rats. Eur J Pharmacol 2001; 20:
115–119.
127 Coupland N, Zedkova L, Sanghera G, Leyton M, Le Melledo JM.
Response to pentagastrin after acute phenylalanine and tyrosine
depletion in healthy men: a pilot study. J Psychiatry Neurosc
2001; 26: 247–251.
128 Nathan PJ, Harrison BJ, Olver JS, Norman TR, Burrows GD,
Stough C. Depletion of serotonin vs dopamine produces double
dissociation on tests of mnemonic function in healthy volun-
teers. Int J Neuropsychopharmacol 2002; 5: S191.
129 Montgomery AJ, Bhagwagar Z, McTavish SFB, Cowen PJ,
Grasby PM. Pilot studies of the effect of dietary tyrosine
depletion on [C-11]raclopride binding. Schizophrenia Res 2002;
53: S155.
130 Harrison BJ, Olver JS, Norman TR, Nathan PJ. Effects of serotonin
and catecholamine depletion on interleukin-6 activation and
mood in human volunteers. Hum Neuropsychopharmacol 2002;
17: 293–297.
131 McTavish SFB, Callado L, Cowen PJ, Sharp T. Comparison of the
effects of alpha-methyl-p-tyrosine and a tyrosine-free amino acid
Monoamine depletion review
L Booij et al
972
Molecular Psychiatry
load on extracellular noradrenaline in the rat hippocampus in
vivo. J Psychopharmacol 1999; 13: 379–384.
132 Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of
Depression. Guilford Press: New York, 1979.
133 Miranda J, Gross JJ, Persons JB, Hahn J. Mood matters:
negative mood induction activates dysfunctional attitudes in
women vulnerable to depression. Cogn Ther Res 1998; 22:
363–376.
134 Segal ZV, Gemar M, Williams S. Differential cognitive response to
a mood challenge following successful cognitive therapy or
pharmacotherapy for unipolar depression. J Abnorm Psychol
1999; 108: 3–10.
135 Van der Does AJW. Cognitive reactivity to sad mood: structure and
validity of a new measure. Behav Res Ther 2002; 40: 105–120.
136 Van der Does AJW. Thought suppression and cognitive vulner-
ability to depression. Br J Clin Psychol (in press).
Monoamine depletion review
L Booij et al
973
Molecular Psychiatry
